Erika Jones - Black Diamond Corporate Finance
| BDTX Stock | USD 4.90 0.03 0.62% |
Executive
Erika Jones is Corporate Finance of Black Diamond Therapeutics
| Age | 39 |
| Address | One Main Street, Cambridge, MA, United States, 02142 |
| Phone | 617 252 0848 |
| Web | https://www.blackdiamondtherapeutics.com |
Black Diamond Management Efficiency
The company has return on total asset (ROA) of (0.3827) % which means that it has lost $0.3827 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7881) %, meaning that it created substantial loss on money invested by shareholders. Black Diamond's management efficiency ratios could be used to measure how well Black Diamond manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.55 in 2024. Return On Capital Employed is likely to drop to -0.65 in 2024. At this time, Black Diamond's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 3 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 100.8 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Eden Fucci | Passage Bio | N/A | |
| Kristina MPH | Alector | N/A | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| Stuart Henderson | Passage Bio | N/A | |
| Gregory Fuest | Passage Bio | N/A | |
| John Lunger | Adaptimmune Therapeutics Plc | 55 | |
| Katie Hogan | Alector | N/A | |
| Karl Whitney | Passage Bio | N/A | |
| Virginia MBA | Alector | N/A | |
| Jan Smith | Revolution Medicines | N/A | |
| BA ACA | Adaptimmune Therapeutics Plc | 54 | |
| Sue Browne | Passage Bio | N/A | |
| Danielle JD | Alector | N/A | |
| Gary MD | Alector | 62 | |
| JD Esq | Passage Bio | 60 | |
| Dana Lynch | Adaptimmune Therapeutics Plc | N/A | |
| Norah Conway | Alector | N/A | |
| Kathleen Borthwick | Passage Bio | 47 | |
| Xiaolin Wang | Revolution Medicines | 53 | |
| Kerry Sharp | Adaptimmune Therapeutics Plc | N/A | |
| MD BA | Adaptimmune Therapeutics Plc | 60 | |
Management Performance
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.38 |
Black Diamond Therap Leadership Team
Elected by the shareholders, the Black Diamond's board of directors comprises two types of representatives: Black Diamond inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Black. The board's role is to monitor Black Diamond's management team and ensure that shareholders' interests are well served. Black Diamond's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Black Diamond's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Melanie Morrison, Sr Operations | ||
| Fang PharmD, Principal CFO | ||
| Christopher Roberts, Advisor | ||
| Elizabeth Montgomery, Chief Officer | ||
| TaiAn Lin, VP Biology | ||
| JD Esq, COO Counsel | ||
| Elizabeth Buck, CoFounder Officer | ||
| Sergey MD, Chief Officer | ||
| David Epstein, President, CoFounder | ||
| Erika Jones, Corporate Finance |
Black Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Black Diamond a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 161.97 M | ||||
| Shares Outstanding | 56.27 M | ||||
| Shares Owned By Insiders | 2.32 % | ||||
| Shares Owned By Institutions | 81.11 % | ||||
| Number Of Shares Shorted | 2 M | ||||
| Price To Book | 2.32 X | ||||
| EBITDA | (86.02 M) | ||||
| Net Income | (82.44 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Black Diamond Therap offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Black Diamond's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Black Diamond Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Black Diamond Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Black Diamond Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Black Stock analysis
When running Black Diamond's price analysis, check to measure Black Diamond's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Black Diamond is operating at the current time. Most of Black Diamond's value examination focuses on studying past and present price action to predict the probability of Black Diamond's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Black Diamond's price. Additionally, you may evaluate how the addition of Black Diamond to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Black Diamond's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Black Diamond. If investors know Black will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Black Diamond listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Return On Assets (0.38) | Return On Equity (0.79) |
The market value of Black Diamond Therap is measured differently than its book value, which is the value of Black that is recorded on the company's balance sheet. Investors also form their own opinion of Black Diamond's value that differs from its market value or its book value, called intrinsic value, which is Black Diamond's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Black Diamond's market value can be influenced by many factors that don't directly affect Black Diamond's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Black Diamond's value and its price as these two are different measures arrived at by different means. Investors typically determine if Black Diamond is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Black Diamond's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.